|Ryan H. Weldon (President)|
Medicis Pharmaceutical is a medical cosmetics company based in Bridgewater, New Jersey. It is a subsidiary of Valeant Pharmaceuticals, which acquired the company in 2012. Medicis is known for products such as Solodyn and Ziana for treating acne, and for Restylane and Dysport for treating facial wrinkles.
1997 Acquisition of GenDerm
In December 1997, Medicis acquired dermatology pharmaceuticals company GenDerm Corporation for $60M in cash. It also acquired Ucyclyd Pharma, a Baltimore-based private company, for $23.4 million in April 1999. Ucyclyd's main product was Buphenyl (sodium phenylbutyrate), used for treating urea cycle disorders. In 2005, they rejected a $2.2 billion unsolicited takeover bid by Mentor.
2011 Sale of LipoSonix to Solta Medical
In September 2011, the company sold its rights to the LipoSonix system to Solta Medical for $35 million. LipoSonix is an ultrasound device intended to help destroy fat deposits in the vicinity of the stomach referred to as "belly fat". For the year, Medicis recorded $721 million in revenue with a gross profit margin of roughly 90 percent.
2012 buyout by Valeant
In September 2012, Canadian-based Valeant Pharmaceuticals and Medicis' management agreed that Valeant would acquire the company for $2.6 billion, or $44/share, 39 percent more than the stock’s Aug. 31 closing price. The deal was subject to shareholder and regulatory approvals. It was the 11th acquisition for Valeant that year and was expected to close the next summer. The transaction was completed in December 2012, with Medicis delisting and becoming a subsidiary of Valeant, after which its board of directors disbanded. Later in December, Valeant dismissed 319 of Medicis' employees and retained 117. Shaknai left the company at the time of the acquisition and Medicis’ executive vice president and COO Ryan Weldon became company group chairman.
2015 Arizona Consumer Fraud Lawsuit and Judicial Precedent
In 2015 Medicis was charged under the Arizona Consumer Fraud Act, and Arizona allowed consumer fraud law to apply against pharmaceutical companies for the first time. Medicis marketed acne cream containing minocycline, known to cause a lupus-like autoimmune response.
- Kelsey Kaustinen (2012-09-05). "Valeant nabs Medicis for $2.6 billion". Drug Discovery News. Retrieved 2012-10-14.
- Alltucker, Ken (30 July 2013). "Medicis headquarters moving to New Jersey". AZ Central. Retrieved 26 November 2015.
- Angela Gonzales for the Phoenix Business Journal. Dec 11, 2012 Valeant, Medicis complete merger with Shacknai out
- Staff. People Nature Biotechnology 24, 366 (2006) doi:10.1038/nbt0306-366
- Staff, The Pharma Letter. Dec 10, 1997 Medicis Completes GenDerm Acquisition
- "Medicis Pharmaceutical Corporation Announces Acquisition of Ucyclyd Pharma Inc.", Gale HealthWire, 1999-04-19, retrieved 2011-09-17
- Feder, Barnaby J. (2005-11-22). "Mentor Leaves Options Open on Its Bid for Medicis". The New York Times. Retrieved 2011-09-09.
- "Medicis agrees to sell LipoSonix system to Solta", Business Week, 2011-09-13, archived from the original on November 2, 2012
- Bloomberg News via The New York Times. Sept 3, 2012. Valeant to Buy Medicis, Maker of Dermatology Drugs
- Mark Scott for The New York Times. Sept 4, 2012. Valeant Sticks to Torrid Pace of Deal-Making
- Angela Gonzales for the Phoenix Business Journal. Dec 18, 2012 How many Medicis employees lost their jobs in Valeant buy? A lot
- Smith, Eleanor. "Arizona Court Revives Product Liability Case, Abolishes Learned Intermediary Doctrine". The National Trial Lawyers. Retrieved 3 April 2018.
- Novak, Edward. "Arizona Applies Consumer Fraud Act to Pharmaceutical Manufacturers". Polsinelli. Retrieved 3 April 2018.
- "Amanda WATTS, An Adult Individual, Plaintiff/Appellant, v. MEDICIS PHARMACEUTICAL CORPORATION, An Arizona Corporation, Defendant/Appellee". FindLaw. Retrieved 3 April 2018.